Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11, 2026 at 3:30 p.m. ET in New York. A live webcast and archived recording will be available under the company's Investors & Media "Events & Presentations" tab for at least 30 days.

News Market Reaction – ZNTL

-9.57%

32 alerts

-9.57% News Effect

+8.4% Peak Tracked

-7.6% Trough Tracked

-$22M Valuation Impact

$205M Market Cap

0.4x Rel. Volume

On the day this news was published, ZNTL declined 9.57%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.4% during that session. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $205M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11^th in New York, NY at 3:30 p.m. ET.

Access to a live webcast of the event, as well as an archived recording, will be available for at least 30 days after each live event concludes under the “Events & Presentations” tab on the Investors & Media section of the Company’s website. 

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at https://www.linkedin.com/company/zentalis-pharmaceuticals.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential for azenosertib to be first-in-class; the potential benefits of azenosertib, including the potential for azenosertib to be an important treatment option for patients with ovarian cancer or other indications; the broad franchise potential of azenosertib; the Company’s biomarker-driven strategy for azenosertib; our anticipated milestones and the timing thereof, including the anticipated timing of DENALI Part 2a dose confirmation and the topline readout from DENALI Part 2, and the initiation, design, conduct and timing of our confirmatory APSENOVA Phase 3 trial; and our planned regulatory strategy for azenosertib and the timing thereof, including the potential for DENALI Part 2 to support an accelerated approval. The terms “anticipate,” “advance,” “believe,” “design,” “develop,” “expect,” “intent,” “look forward,” “on track,” “plan,” “position,” “potential,” “runway,” “strategy,” “target,” and “will” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

When will Zentalis (ZNTL) present at Guggenheim's Emerging Outlook: Biotech Summit 2026?

Zentalis will present on February 11, 2026 at 3:30 p.m. ET. According to the company, the presentation is a fireside discussion during the summit in New York, and management participation is intended to discuss late-stage clinical progress.

How can investors watch Zentalis (ZNTL) at the February 11, 2026 Guggenheim conference?

Investors can access a live webcast of the event and an archived recording for at least 30 days. According to the company, both will be posted under the Investors & Media "Events & Presentations" tab on the company's website.

What will Zentalis management discuss at the Guggenheim Biotech Summit on February 11, 2026?

Management will participate in a fireside discussion focused on the company's late-stage development programs. According to the company, the discussion will address the investigational WEE1 inhibitor azenosertib and its biomarker-driven approach for ovarian cancer.

Will Zentalis (ZNTL) provide an archived recording of its Guggenheim presentation?

Yes, an archived recording will be available for at least 30 days after the live event concludes. According to the company, the recording will be posted in the Investors & Media "Events & Presentations" section on its website.

Where is Guggenheim's Emerging Outlook: Biotech Summit 2026 where Zentalis (ZNTL) will appear?

The summit takes place in New York, and Zentalis is scheduled for a 3:30 p.m. ET fireside discussion on February 11, 2026. According to the company, the event is part of Guggenheim's Emerging Outlook: Biotech Summit 2026.